ethanol
Approved
Jan 17, 1946
Alcohols exhibit rapid broad-spectrum antimicrobial activity against vegetative bacteria (including mycobacteria), viruses, and fungi but are not sporicidal. They are, however, known to inhibit sporulation and spore germination, but this effect is reversible. Because of the lack of sporicidal activity, alcohols are not recommended for sterilization but are widely used for both hard-surface disinfection and skin antisepsis. Lower concentrations may also be used as preservatives and to potentiate the activity of other biocides. Many alcohol products include low levels of other biocides (in particular chlorhexidine), which remain on the skin following evaporation of the alcohol, or excipients (including emollients), which decrease the evaporation time of the alcohol and can significantly increase product efficacy. Ethanol in combination with: chlorhexidine gluconate 1% was approved to use in surgical hand antiseptic. It significantly reduces the number of microorganisms on the hands and forearms prior to surgery or patient care. Ethanol is also used as a co-solvent to dissolve many insoluble drugs and to serve as a mild sedative in some medicinal formulations. Ethanol is metabolized by the hepatic enzyme alcohol dehydrogenase. Ethanol affects the brain’s neurons in several ways. It alters their membranes as well as their ion channels, enzymes, and receptors. Alcohol also binds directly to the receptors for acetylcholine, serotonin, GABA, and the NMDA receptors for glutamate. The sedative effects of ethanol are mediated through binding to GABA receptors and glycine receptors (alpha 1 and alpha 2 subunits). It also inhibits NMDA receptor functioning. In its role as an anti-infective, ethanol acts as an osmolyte or dehydrating agent that disrupts the osmotic balance across cell membranes. — NCATS
Clinical trial activity
308 trials · 272 clinical orgs · 12 marketing orgs
Earliest trial started Jan 1, 1997 (NCT00000263)
Timeline
1940s
1970s
- Feb 26, 1974
Hospira — Marketing Organization
2000s
2010s
- Jun 21, 2018
Belcher Pharmaceuticals — Marketing Organization
- Jun 21, 2018
Belcher Pharmaceuticals — NDA Secondary Org
- Jun 21, 2018
BPI — Marketing Organization
- Jun 21, 2018
BPI — NDA Secondary Org
2020s
- Jun 23, 2025
Accord Research — Marketing Organization
- Jun 23, 2025
Esteve Labs — Marketing Organization
- Jun 23, 2025
X Gen Pharmaceuticals — Marketing Organization
- Jul 9, 2025
Ingenus Pharmaceuticals — Marketing Organization
- Oct 23, 2025
ROYAL PHARMS — Marketing Organization
Indications
Studied for
- Abscess · Early Phase 1
- Acne Vulgaris · Phase 4
- Acute Kidney Injury · Phase 3
- Acute-On-Chronic Liver Failure · Phase 2/Phase 3
- Adenoma · Phase 1
- Alcohol Drinking · Phase 4
- Alcoholic Intoxication · Phase 3
- Alcohol-Induced Disorders · Phase 3
- Alcoholism · Phase 4
- Alcohol-Related Disorders · Phase 1
- Alopecia · Phase 2
- Altruism · Phase 1/Phase 2
- Amphetamine-Related Disorders · Phase 1
- Analgesics, Opioid · Phase 1
- Antisepsis · Phase 4
- Anxiety Disorders · Phase 1
- Atrial Fibrillation · Phase 2/Phase 3
- Automobile Driving · Phase 3
- Bacteremia · Phase 4
- Bacterial Infections · Phase 4
- Bariatric Surgery · Early Phase 1
- Binge Drinking · Phase 2
- Bipolar Disorder · Phase 1
- Blood-Borne Infections · Phase 3
- Blood Loss, Surgical · Phase 3
- BRCA1 Protein · Phase 2
- Breast Neoplasms · Phase 2
- Cancer Pain · Phase 4
- Cannabis · Phase 2
- Carcinoma, Hepatocellular · Phase 3
- Cardiomyopathies · Phase 2
- Catheterization, Central Venous · Phase 4
- Catheter-Related Infections · Phase 4
- Catheters · Phase 3
- Central Nervous System · Phase 1
- Central Nervous System Depressants · Early Phase 1
- Cigarette Smoking · Phase 4
- Cocaine-Related Disorders · Phase 4
- Constipation · Phase 2
- Coronavirus Infections · Phase 2
- COVID-19 · Phase 3
- Dental Plaque · Phase 3
- Depression · Phase 2
- Diabetes Mellitus · Phase 4
- Diabetes Mellitus, Type 1 · Phase 4
- Diabetes Mellitus, Type 2 · Phase 2
- Dihydroxyphenylalanine · Phase 1
- Disruptive, Impulse Control, and Conduct Disorders · Phase 2
- Drinking Behavior · Early Phase 1
- Driving Under the Influence · Phase 2
- Drug Interactions · Phase 1
- Drug-Related Side Effects and Adverse Reactions · Phase 1/Phase 2
- Drugs, Investigational · Phase 2
- Dysmenorrhea · Phase 2
- Endometriosis · Early Phase 1
- Erectile Dysfunction · Phase 1
- Essential Hypertension · Phase 3
- Ethanol · Early Phase 1
- Fibrosis · Phase 2/Phase 3
- General Surgery · Phase 4
- Genetics · Phase 1
- Gingivitis · Phase 4
- Hair · Phase 4
- Hand Hygiene · Phase 4
- Hand Injuries · Phase 4
- Healthy Volunteers · Phase 4
- Hemodialysis, Home · Phase 1/Phase 2
- Hepatitis C · Phase 1
- Herpes Labialis · Phase 2
- Herpesvirus 1, Human · Early Phase 1
- HIV Infections · Phase 2
- Hyperhidrosis · Phase 1
- Hypertension · Phase 3
- Hypoglycemia · Phase 4
- Infections · Phase 3
- Inflammation · Phase 1/Phase 2
- Keratosis, Actinic · Phase 2
- Ketosis · Phase 2/Phase 3
- Kidney Failure, Chronic · Phase 2
- Lead Poisoning · Phase 4
- Leukemia · Phase 1/Phase 2
- Liver Diseases, Alcoholic · Phase 4
- Lymphoma · Phase 1/Phase 2
- Lymphoproliferative Disorders · Phase 1/Phase 2
- Magnetic Resonance Imaging · Phase 2/Phase 3
- Major Depressive Disorder · Phase 1
- Marijuana Use · Phase 4
- Men · Phase 1
- Morals · Phase 3
- Multiple Myeloma · Phase 1/Phase 2
- Mutation · Phase 2
- Myelodysplastic Syndromes · Phase 1/Phase 2
- Myeloproliferative Disorders · Phase 1/Phase 2
- Neonatology · Phase 2
- Neoplasms · Phase 4
- Neoplasms, Cystic, Mucinous, and Serous · Phase 1
- Neuralgia · Phase 2
- Neurobehavioral Manifestations · Phase 2
- Neuroblastoma · Phase 1
- Neutropenia · Phase 3
- Nevus · Early Phase 1
- Nicotine · Phase 1
- Obesity · Phase 2
- Osteoarthritis · Phase 4
- Osteoarthritis, Hip · Phase 4
- Overweight · Phase 2
- Pain · Phase 4
- Pain Management · Phase 4
- Pancreatic Cyst · Phase 3
- Pancreatic Neoplasms · Phase 4
- Pharmacokinetics · Phase 3
- Phosphodiesterase Inhibitors · Phase 1
- Physiological Effects of Drugs · Early Phase 1
- Placebos · Phase 2
- Prediabetic State · Phase 3
- Prostatic Hyperplasia · Phase 1/Phase 2
- Psoriasis · Phase 1/Phase 2
- Psychological Distress · Early Phase 1
- Psychomotor Disorders · Early Phase 1
- Pulpitis · Early Phase 1
- Root Resorption · Early Phase 1
- Sepsis · Phase 3
- Sexual Behavior · Phase 1
- Sexually Transmitted Diseases · Phase 1
- Short Bowel Syndrome · Phase 2
- Sleep · Phase 2
- Sleep Initiation and Maintenance Disorders · Phase 4
- Stress, Physiological · Early Phase 1
- Substance-Related Disorders · Phase 1
- Surgical Wound Infection · Phase 3
- Tachycardia, Ventricular · Phase 2/Phase 3
- Thyroid Diseases · Phase 4
- Thyroid Nodule · Phase 1
- Tobacco Use · Early Phase 1
- Toes · Phase 4
- Tooth Mobility · Early Phase 1
- Toxicity Tests · Early Phase 1
- Tremor · Phase 2
- Urinary Catheters · Phase 1
- Venous Cutdown · Phase 4
- Viruses · Early Phase 1
Mechanism of action
- Cell membraneDISRUPTING AGENT
Cell membrane disrupting agent
Combination products
avagar
with chlorhexidine
Approval history
- approvedJan 17, 1946
- approvedJan 17, 1946
Chemistry & pharmacology
SMILES
CCO- Mol. weight
- 46.0684 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- Yes
- Chirality
- Achiral Molecule
- Inorganic
- No
- Polymer
- No
- Delivery
- Parenteral, Topical
- Availability
- Over the Counter
Oral
No
Parenteral
Yes
Topical
Yes
Sources
- WikipediaEthanol ↗
- NCATS3K9958V90M ↗
- ChEMBLCHEMBL545 ↗
Also known as
- 1-hydroxyethane
- 1-hydroxyethane
- 40 g ethanol
- alcohol
- alcohol
- alcohol
- alcohol
- alcohol
- alcohol
- alcohol
- alcohol
- alcohol anhydrous
- alcohol anhydrous
- alcohol denatured
- alcohol denatured
- alcohol, denatured
- alcohol, denatured
- alcohol, diluted
- alcohol, diluted
- alcohol (ethyl)
- alcohol (ethyl)
- alcohol etílico
- alcohol etílico
- alcohol, rubbing
- alcohol, rubbing
- alcool éthylique
- alcool éthylique
- alkohol
- alkohol
- äthanol
- äthanol
- äthylalkohol
- äthylalkohol
- dehydrated alcohol
- dehydrated alcohol
- dehydrated ethanol
- dehydrated ethanol
- e1510
- e1510
- etanol
- etanol
- ethanol
- ethanol
- ethanol
- ethanol
- ethanol
- ethanol
- ethanol
- ethanol
- éthanol
- éthanol
- ethyl alcohol
- ethyl alcohol
- ethyl alcohol
- ethyl alcohol
- ethyl alcohol
- gelified ethanol
- grain alcohol
- grain alcohol
- grain alcohol
- hazel
- hazel
- hydroxyethane
- hydroxyethane
- methylated mineral
- methylcarbinol
- methylcarbinol
- prf
- spirigel
- spiritus vini
- spiritus vini
- surg
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT07027839 | Phase 1 | Dec 2, 2025 | National Institute of Mental Health (NIMH) |
| NCT07282405 | N/A | Nov 11, 2025 | University of Wisconsin |
| NCT07176208 | Phase 1 | Sep 22, 2025 | Food and Drug Administration, Spaulding Clinical Research Inc. |
| NCT07083765 | Phase 3 | Sep 1, 2025 | Ablative Solutions, Inc., Piedmont Healthcare, University of Basel |
| NCT07125534 | N/A | Aug 9, 2025 | University of Illinois |
| NCT06719908 | Phase 1 | Jul 1, 2025 | Afasci Inc |
| NCT06865872 | N/A | Apr 18, 2025 | National Institute on Alcohol Abuse and Alcoholism (NIAAA), University of Colorado, Denver |
| NCT06815237 | Phase 2/Phase 3 (Phase 3) | Mar 31, 2025 | National Institute on Alcohol Abuse and Alcoholism (NIAAA), University of Pennsylvania |
| NCT06819189 | Phase 1 | Mar 20, 2025 | National Institute on Alcohol Abuse and Alcoholism (NIAAA) |
| NCT06627803 | N/A | Feb 28, 2025 | National Institute on Alcohol Abuse and Alcoholism (NIAAA), University of Southern California |
| NCT06747364 | N/A | Feb 28, 2025 | National Institute on Alcohol Abuse and Alcoholism (NIAAA), University of North Texas, University of Texas, San Antonio |
| NCT06887322 | Phase 1/Phase 2 (Phase 2) | Feb 13, 2025 | Padjadjaran University |
| NCT06822257 | N/A | Feb 1, 2025 | Carnegie Mellon University, National Institute on Alcohol Abuse and Alcoholism (NIAAA) |
| NCT06712602 | Phase 1 | Jan 31, 2025 | National Institute on Alcohol Abuse and Alcoholism (NIAAA), Pop Test Oncology LLC, University of Kentucky |
| NCT06293040 | Phase 1 | Sep 26, 2024 | Johns Hopkins University, National Institute on Drug Abuse (NIDA) |
| NCT06576674 | N/A | Sep 3, 2024 | University of North Carolina at Chapel Hill |
| NCT06559878 | N/A | Sep 1, 2024 | University of Helsinki |
| NCT06579521 | N/A | Aug 31, 2024 | National Institute on Alcohol Abuse and Alcoholism (NIAAA), University of Washington |
| NCT06520384 | N/A | Jul 25, 2024 | Tanta University |
| NCT06326684 | Early Phase 1 (Phase 1) | Jun 7, 2024 | National Institute on Alcohol Abuse and Alcoholism (NIAAA), University of Kentucky |
Organizations
Research & Development (272)
Marketing (17)
| Organization | Org type | Relationship | Date |
|---|---|---|---|
| 3M | For profit | MKTG | Jun 7, 2001 |
| 3M | For profit | NDA2 | Jun 7, 2001 |
| Accord Research | For profit | MKTG | Jun 23, 2025 |
| B. Braun | For profit | MKTG | Jan 17, 1946 |
| B. Braun | For profit | NDA2 | Jan 17, 1946 |
| B. Braun | For profit | NDA | Jan 17, 1946 |
| BPI | For profit | MKTG | Jun 21, 2018 |
| BPI | For profit | NDA2 | Jun 21, 2018 |
| Baxter | For profit | MKTG | — |
| Belcher Pharmaceuticals | For profit | MKTG | Jun 21, 2018 |
| Belcher Pharmaceuticals | For profit | NDA2 | Jun 21, 2018 |
| Esteve Labs | For profit | MKTG | Jun 23, 2025 |
| Hospira | For profit | MKTG | Feb 26, 1974 |
| Ingenus Pharmaceuticals | For profit | MKTG | Jul 9, 2025 |
| Miles | For profit | MKTG | — |
| ROYAL PHARMS | For profit | MKTG | Oct 23, 2025 |
| X Gen Pharmaceuticals | For profit | MKTG | Jun 23, 2025 |